Online citations, reference lists, and bibliographies.
← Back to Search

Immune Related Adverse Events Associated With Anti-CTLA-4 Antibodies: Systematic Review And Meta-analysis

A. Bertrand, M. Kostine, T. Barnetche, M. Truchetet, T. Schaeverbeke
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BackgroundTargeting CTLA-4 is a recent strategic approach in cancer control: blocking CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T-lymphocyte proliferation. This induction of a tolerance break against the tumor may be responsible for immune-related adverse events (irAEs). Our objective was to assess the incidence and nature of irAEs in oncologic patients receiving anti-CTLA-4 antibodies (ipilimumab and tremelimumab).MethodsA systematic search of literature up to February 2014 was performed in MEDLINE, EMBASE, and Cochrane databases to identify relevant articles. Paired reviewers independently selected articles for inclusion and extracted data. Pooled incidence was calculated using R©, package meta.ResultsOverall, 81 articles were included in the study, with a total of 1265 patients from 22 clinical trials included in the meta-analysis. Described irAEs consisted of skin lesions (rash, pruritus, and vitiligo), colitis, and less frequently hepatitis, hypophysitis, thyroiditis, and some rare events such as sarcoidosis, uveitis, Guillain-Barré syndrome, immune-mediated cytopenia and polymyalgia rheumatic/Horton. The overall incidence of all-grade irAEs was 72 % (95 % CI, 65–79 %). The overall incidence of high-grade irAEs was 24 % (95 % CI, 18–30 %). The risk of developing irAEs was dependent of dosage, with incidence of all-grade irAEs being evaluated to 61 % (95 % CI, 56–66 %) for ipilimumab 3 mg/kg and 79 % (95 % CI, 69–89 %) for ipilimumab 10 mg/kg. Death due to irAEs occurred in 0.86 % of patients.The median time of onset of irAEs was about 10 weeks (IQR, 6–12) after the onset of treatment, corresponding with the first three cycles but varied according to the organ system involved. Such immune activation could also be indicative for tumor-specific T-cell activation and irAE occurrence was associated with clinical response to CTLA-4 blocking in 60 % of patients.ConclusionThe price of potential long-term survival to metastatic tumors is an atypical immune toxicity, reflecting the mechanism of action of anti-CTLA-4 antibodies. A better knowledge of these irAEs and its management in a multidisciplinary approach will help to reduce morbidity and therapy interruptions.
This paper references
10.1186/s40425-014-0035-z
Ipilimumab in patients with melanoma and autoimmune disease
Chrisann Kyi (2014)
10.1093/annonc/mdt027
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.
J. Delyon (2013)
10.1200/JCO.2012.44.6112
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
A. Ribas (2013)
10.1007/s00262-014-1607-y
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
Magnus Pedersen (2014)
10.1097/IOP.0000000000000033
Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression.
G. Borodic (2014)
10.1016/S1470-2045(09)70334-1
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
J. Wolchok (2010)
10.1136/bmj.d5928
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
J. P. Higgins (2011)
10.1158/1078-0432.CCR-09-2870
Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
C. Ralph (2010)
10.1007/s10637-009-9376-8
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
E. Hersh (2009)
10.1016/j.jaad.2013.07.028
Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab.
Ross B Reule (2013)
10.1007/s00262-011-1089-0
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
R. Danielli (2011)
10.1186/1752-1947-8-240
Serious haematological toxicity during and after ipilimumab treatment: a case series
E. Simeone (2014)
10.1200/JCO.2011.39.3298
Pulmonary sarcoid-like granulomatosis induced by ipilimumab.
G. Berthod (2012)
10.1007/s12032-010-9606-0
Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
K. Harmankaya (2011)
10.1111/cei.12367
Abatacept (cytotoxic T lymphocyte antigen 4‐immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non‐responding to anti‐tumour necrosis factor‐α agents
A. Picchianti Diamanti (2014)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1200/JCO.2005.06.205
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
10.6004/JNCCN.2014.0105
Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
Neelima N Nallapaneni (2014)
10.1056/NEJMoa1406498
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
A. Snyder (2014)
10.1097/CJI.0b013e3181eec14c
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
R. Royal (2010)
10.1001/jamadermatol.2014.2233
Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
Shirwa Sheik Ali (2015)
10.1200/JCO.2011.37.9693
Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.
W. Vogel (2012)
10.1200/JCO.2013.51.1683
Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.
D. Johnson (2015)
Ipilimumab-induced immune-related renal failure--a case report.
P. Forde (2012)
10.1016/j.clineuro.2014.06.011
Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosis
Yosef G. Chodakiewitz (2014)
10.1200/JCO.2011.38.7886
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma.
M. Maur (2012)
10.1093/annonc/mdr028
Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.
S. Wilgenhof (2011)
10.1158/1078-0432.CCR-09-1024
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
J. Weber (2009)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
10.1097/CJI.0b013e31829fb7a2
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
D. Le (2013)
10.1155/2013/857519
Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
A. Tarhini (2013)
10.1097/CJI.0b013e318156e47e
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
J. Yang (2007)
10.1126/science.1195568
Has the Microbiota Played a Critical Role in the Evolution of the Adaptive Immune System?
Y. K. Lee (2010)
10.4049/jimmunol.1302455
Humanized Mice as a Model for Aberrant Responses in Human T Cell Immunotherapy
Nalini K. Vudattu (2014)
10.1016/1074-7613(95)90125-6
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival
GY Ku (2010)
10.1188/11.CJON.393-403
Atypical clinical response patterns to ipilimumab.
B. Ledezma (2011)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1097/CMR.0b013e32835fb524
Ipilimumab-induced acute severe colitis treated by infliximab.
C. Pages (2013)
10.1055/s-0033-1355337
Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy.
A. Lammert (2013)
10.1016/j.jaad.2014.02.035
Ipilimumab in patients with cancer and the management of dermatologic adverse events.
M. Lacouture (2014)
10.4158/EP11273.OR
Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series.
L. Min (2012)
Ipilimumab immune-related adverse reactions: a case report.
L. Anderson (2013)
10.1200/JCO.2005.04.5716
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Kimberly E. Beck (2006)
10.1016/j.annder.2013.02.029
[Orbital myositis associated with ipilimumab].
M. Lecouflet (2011)
10.1016/j.jaad.2012.12.963
The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.
Kira Minkis (2013)
10.1097/RLU.0b013e3182639765
Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab.
B. van der Hiel (2013)
10.1210/JC.2006-2484
Transient hypophysitis after cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade.
Stephanie A. Shaw (2007)
10.1093/annonc/mdu441
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.
C. Lebbé (2014)
10.1007/s00262-008-0627-x
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
Ilyssa O. Gordon (2008)
10.1097/CMR.0000000000000017
Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.
S. Pintova (2013)
10.1007/s12032-010-9794-7
Hyponatremia associated with Ipilimumab-induced hypophysitis
Zachary R Barnard (2011)
10.1634/THEONCOLOGIST.12-7-873
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
A. Ribas (2007)
10.1016/S1470-2045(12)70090-6
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
K. Margolin (2012)
10.1097/CJI.0b013e31828eed39
Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
S. Wilgenhof (2013)
10.1097/CMR.0b013e32835c7e68
Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
Sebastian G Bernardo (2013)
10.1186/1479-5876-9-204
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
O. Hamid (2010)
a novel Bertrand et al
S Sheik Ali (2015)
10.1158/1078-0432.CCR-07-0187
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
10.1007/s00262-008-0642-y
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
A. D. Giacomo (2008)
10.3747/co.20.1265
Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases.
H. Assi (2013)
10.1200/JCO.2010.32.2206
Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy.
Katarzyna Chmiel (2011)
10.1002/ibd.22846
Lymphocytic colitis secondary to ipilimumab treatment.
Alejandro García-Varona (2013)
10.1017/S0317167100007939
Autoimmune inflammatory myopathy after treatment with ipilimumab.
Gary R W Hunter (2009)
10.1111/bjd.13058
First report of ipilimumab‐induced Grover disease
J. Munoz (2014)
10.1378/chest.12-1467
Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.
I. Barjaktarevic (2013)
10.2214/AJR.12.9751
Ipilimumab-associated colitis: CT findings.
K. Kim (2013)
10.1097/CJI.0b013e31827807dd
A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.
C. Gaudy-Marqueste (2013)
10.3174/ajnr.A1623
Ipilimumab-Induced Hypophysitis: MR Imaging Findings
K. Carpenter (2009)
Immunol. Cell Biol.
M. Fitzgerald (1995)
10.1002/art.38282
Drug‐Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA‐4
B. Goldstein (2014)
10.1097/CJI.0b013e318193a206
Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.
S. Bhatia (2009)
10.1002/mus.23830
Multifocal radiculoneuropathy during ipilimumab treatment of melanoma
G. Manousakis (2013)
10.1038/bjc.2014.126
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
V. Chiarion-Sileni (2014)
10.1097/IOP.0000000000000081
A case report of orbital inflammatory syndrome secondary to ipilimumab.
A. D. Henderson (2015)
10.1001/ARCHDERM.142.2.166
Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
Samer H Jaber (2006)
Hypophysite lymphocytaire. Endocrinologie-Nutrition, 10-023-D-10
J Salenave (2007)
10.1007/s00262-013-1418-6
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
A. M. Di Giacomo (2013)
10.1542/peds.2015-2776BBBBB
Immune Dysregulation in Human Subjects With Heterozygous Germline Mutations in CTLA4
T. Fleisher (2015)
10.1056/NEJMc1110923
Hemophilia A induced by ipilimumab.
J. Delyon (2011)
10.1530/EJE-10-0833
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy.
L. Min (2011)
10.3109/07357907.2013.793699
Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study
P. Queirolo (2013)
10.1159/000362614
New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment
K. Murphy (2014)
10.1007/s00262-010-0958-2
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
A. M. Di Giacomo (2010)
YERVOY (ipilimumab): immune-mediated adverse reaction management guide
Bristol-Myers Squibb (2011)
10.1158/1078-0432.CCR-12-3080
Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
C. Robert (2013)
10.1093/annonc/mdt107
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
S. Slovin (2013)
10.1111/j.1600-065X.2009.00775.x
Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells
Hélène Bour-Jordan (2009)
Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy.
Jingjing Sun (2008)
10.1002/cncr.23086
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
S. O’Day (2007)
10.1093/annonc/mdq013
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
S. O’Day (2010)
10.1097/RLU.0b013e318248549a
Ipilimumab-induced colitis on FDG PET/CT.
A. Lyall (2012)
10.1371/journal.pone.0053745
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Caroline J Voskens (2013)
Ipilimumabinduced hypophysitis: MR imaging findings
KJ Carpenter (2009)
10.1093/neuonc/nou001
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.
B. Liao (2014)
J Immunother
(2009)
10.1097/CJI.0000000000000041
Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma.
Pauline du Rusquec (2014)
10.1038/nrclinonc.2014.174
Decade in review—cancer immunotherapy: Entering the mainstream of cancer treatment
S. Rosenberg (2014)
10.1158/1078-0432.CCR-10-0569
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
B. Carthon (2010)
10.1159/000161122
Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
A. Eckert (2008)
10.1007/s10637-014-0092-7
Kidney injuries related to ipilimumab
H. Izzedine (2014)
10.1097/CMR.0b013e32832e0bff
Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
K. Kähler (2009)
10.1007/s12020-014-0199-9
Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports
Joke Marlier (2014)
10.1200/JCO.2010.28.3994
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
K. Chung (2010)
10.1097/CJI.0b013e31819aa40b
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
M. Akhtari (2009)
10.1136/practneurol-2012-000447
Neurological immune-related adverse events of ipilimumab
I. Bot (2013)
10.1016/j.jaad.2013.11.022
Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma.
Rachel L. Kyllo (2014)
10.1530/EJE-12-0167
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
A. Juszczak (2012)
10.3109/01676830.2014.949792
Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
E. Mcelnea (2014)
10.1210/jc.2014-2306
Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
A. Faje (2014)
Phase III randomized clinical trial comparing tremelimumab with standardof-care chemotherapy in patients with advanced melanoma
A Ribas (2013)
10.1016/S1040-1741(08)79104-8
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
M. Gordon (2008)
10.1177/1078155211411001
Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma
S. Ahmad (2012)
10.1097/01.CJI.0000178913.41256.06
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
J. Blansfield (2005)
10.3109/0284186X.2012.682630
Severe colitis while responding to ipilimumab in metastatic melanoma
M. Slingerland (2012)
10.1097/CJI.0b013e31817fd8f3
Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade
W. Breunis (2008)
10.1007/s10637-011-9787-1
Severe meningo-radiculo-nevritis associated with ipilimumab
F. Bompaire (2011)
10.2478/pjs-2014-0017
Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab - case report.
Paweł Dilling (2014)
10.1200/JCO.2011.29.15_SUPPL.8583
Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
R. Ibrahim (2011)
10.1053/j.seminoncol.2010.09.006
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.
L. Calabrò (2010)
10.1007/s10620-012-2140-5
Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
D. Kleiner (2012)
10.1530/EJE-14-0845
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
F. Albarel (2015)
10.1097/MCG.0b013e31828f1d51
Ipilimumab-induced perforating colitis.
K. Mitchell (2013)
10.1046/j.1440-1711.1999.00795.x
The role of CTLA‐4 in the regulation of T cell immune responses
K. McCoy (1999)
10.1093/annonc/mdt291
Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).
D. McDermott (2013)
10.1097/RLU.0000000000000606
Ipilimumab-induced hepatitis on 18F-FDG PET/CT in a patient with malignant melanoma.
R. Raad (2015)
10.1089/cbr.2008.0607
Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
D. Minor (2009)
10.1200/JCO.2013.49.2314
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
E. Lipson (2014)
10.1183/09031936.00107912
Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy
C. Tissot (2013)
Ipilimumab-induced immunerelated renal failure – a case report
PM Forde (2012)
10.1097/CCO.0b013e328341edff
Autoimmunity and treatment outcome in melanoma
Marna G. Bouwhuis (2011)
10.1038/nm0303-269
Immunotherapy: past, present and future
T. Waldmann (2003)
10.1159/000353408
Melanoma-Associated Retinopathy Treated with Ipilimumab Therapy
A. Audemard (2013)
10.1007/s10620-009-0839-8
Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
J. Lord (2009)
Hypophysite lymphocytaire
J Salenave (2007)
10.1016/J.ANNDER.2013.02.029
Myosite orbitaire associée à un traitement par ipilimumab
M. Lecouflet (2011)
10.1038/nrc3239
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
10.1084/jem.20130579
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
Tyler R. Simpson (2013)
10.1016/j.mayocp.2013.01.015
Association between ipilimumab and celiac disease.
Nicole M. Gentile (2013)
10.1200/JCO.2008.16.1927
Phase I/II study of ipilimumab for patients with metastatic melanoma.
J. Weber (2008)
10.1684/ejd.2014.2297
Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma — simultaneous occurrence of pyoderma gangrenosum and colitis
B. Rudolph (2014)
10.1097/01720610-201108000-00017
Case of the month. Autoimmune colitis secondary to CTLA-4 blockade.
Angie Tsiaras (2011)
10.1097/RLU.0b013e31828da691
Ipilimumab-induced immunomediated adverse events: possible pitfalls in (18)F-FDG PET/CT interpretation.
L. Gilardi (2014)
10.1200/JCO.2005.01.109
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
A. Ribas (2005)
10.1200/JCO.2012.47.5095
Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab.
D. Minor (2013)
Identification and management of toxicities from immune checkpoint-blocking drugs.
B. Teply (2014)
10.1056/NEJMc0904283
Anti-CTLA4 antibody-induced lupus nephritis.
F. Fadel (2009)
10.1053/j.gastro.2012.01.042
Enterocolitis in a patient being treated with ipilimumab for metastatic melanoma.
C. Koch (2012)
10.1200/JCO.2013.49.7735
Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab.
J. Luke (2015)



This paper is referenced by
10.1007/s11912-018-0671-4
Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors
L. Kottschade (2018)
10.12788/jhm.2925
Immunotherapy-Induced Colitis: An Emerging Problem for the Hospitalist
J. Marin-Acevedo (2018)
10.1016/j.coi.2017.01.005
Immunoprofiling as a predictor of patient's response to cancer therapy-promises and challenges.
D. Bethmann (2017)
10.1159/000464285
Tremelimumab-Induced Graves Hyperthyroidism

E. H. Gan (2017)
TUMOR IMMUNOTHERAPY: MECHANISMS OF ACQUIRED RESISTANCE AND CHARACTERIZATION OF IMMUNE RELATED TOXICITIES
A. Jaiswal (2018)
10.1172/JCI135947
Haploinsufficiency of immune checkpoint receptor CTLA4 induces a distinct neuroinflammatory disorder.
M. K. Schindler (2020)
10.1007/978-1-4939-9773-2_4
Germline Genetics in Immuno-oncology: From Genome-Wide to Targeted Biomarker Strategies.
T. Kirchhoff (2020)
10.1080/14712598.2019.1650911
Immune therapy, a double-edged sword for oncolytic viruses
Ryan M McCormack (2019)
10.1007/s00262-019-02318-8
Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition
Vylyny Chat (2019)
10.1159/000493183
Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors
Jean Kuo (2018)
10.1186/s40425-016-0117-1
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
V. Koelzer (2016)
10.7812/tpp/19.093
Immunotherapy Outcomes in Advanced Melanoma in Relation to Age.
K. Joshi (2020)
Title The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
Louise E. Daly (2019)
10.1016/j.autrev.2018.05.002
Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
J. Narváez (2018)
10.1186/s40425-018-0408-9
A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
P. Friedlander (2018)
10.1038/s41591-018-0238-9
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang (2018)
10.1186/s40425-017-0300-z
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov (2017)
10.1016/j.bcp.2019.06.002
Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes.
H. E. Marei (2019)
10.2217/mmt-2018-0009
Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population
Khor Zhong Wei (2019)
10.1158/1535-7163.MCT-19-0495
Combination Immunotherapy with Cytotoxic T-Lymphocyte–Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis
T. Sun (2019)
10.3233/KCA-170017
Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review
M. Ornstein (2017)
10.1038/s41598-019-50574-6
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
Y. Eun (2019)
10.2147/DDDT.S196316
Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis
Hang Xu (2019)
10.2337/dbi18-0002
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Angeliki M Stamatouli (2018)
10.1016/j.conctc.2020.100575
Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) – protocol for a multi-center, single-arm phase IIa trial
B. Frye (2020)
10.18103/imr.v3i4.408
Autoimmune T-cells induced by low dose immune checkpoint blockade could be a powerful therapeutic tool in cancer through activation of eliminative inflammation and immunity
T. Bakacs (2017)
10.1186/s12885-020-06763-y
Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
J. Bögeholz (2020)
10.1055/S-0043-112730
Management of Immune-Mediated Paraneoplastic Neurological Disorders
I. Ayzenberg (2017)
The Window Is Wide Open: Evaluating the Rationale for Window of Opportunity Studies in Breast Cancer with a Focus on Immune Therapies
N. Nixon (2017)
IpiColitis: ipilimumab-induced colitis with a wide spectrum of histological features
Brandon Trac (2018)
10.2174/1574886313666180730114309
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
K. Plachouri (2019)
10.1016/j.mayocp.2019.12.034
64-Year-Old Man With Altered Mental Status.
Tyler J Schmidt (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar